Akers Biosciences, Inc.

Reducing the cost of healthcare through faster, easier

diagnostics

1

All statements pertaining to future financial and/or operating results, future

growth in research, technology, clinical development, and potential

opportunities for Akers Biosciences, Inc. (Akers or the Company) products and

services, along with other statements about the future expectations, beliefs,

goals, plans, or prospects expressed by management constitute forward-looking

statements.

Any statements that are not historical fact (including, but not limited, to

statements that contain words such as "will," "believes," "plans," "anticipates,"

"expects," "estimates") should also be considered to be forward-looking

statements.

Forward-looking statements involve risks and uncertainties, including, without

limitation, risks inherent in the development and/or commercialization of

potential products, uncertainty in the results of clinical trials or regulatory

approvals, need and ability to obtain future capital, and maintenance of

intellectual property rights and other risks discussed in the Company’s recent

Form 10-K and other reports filed with the Securities and Exchange

Commission which are available for review at www.sec.gov.

Actual results may differ materially from the results anticipated in these

forward-looking statements and as such should be evaluated together with the

many uncertainties that affect the Company's business.

The Company disclaims any intent or obligation to update these forward-looking

statements.

2

Forward

Looking

Statements

3

Reducing the

cost of

healthcare

through

faster, easier

diagnostics

Growing

Product Portfolio

Growing

Revenues

Growing

Global Market

Five products launched and

commercialized

Robust pipeline will result in

eleven products in market by

end of 2016

Revenues up 200% over 3

years

Expanded sales and

marketing organization in

high growth markets

Point-of-care diagnostics

market to reach $27.5bn by

2018

Need for significant

healthcare cost savings is

driving demand for new

point-of-care tests

• In Vitro Diagnostics (IVD) are tests that take place outside of the body

• Key factors driving IVD market growth:

– increasing demand for rapid and non-invasive diagnostics

– availability of more point-of-care tests

– aging population

4

Akers

addresses the

large and

growing global

IVD market

Largest IVD Markets

USA (47%)

Western Europe (31%)

Fastest Growing IVD Market

Asia Pacific (CAGR 11.3%)

The IVD market

outpaces

pharma industry

growth

5

Impact of new

healthcare

insurance

system in US

More lives insured = more testing

12 million more Americans have gained coverage in 2015; 21

million more predicted in 2016

• Screening costs are now fully covered for these conditions:

• Cholesterol

• Diabetes

• Obesity

• Alcohol misuse

• Chlamydia

• Approximately 15% of all physician visits involve tests for one

of the above - Akers Bio is targeting each of these conditions

Traditional Testing

(ELISA)

PIFA-PLUSS®

(Akers Bio)

Equipment

and Process

CapEx required

Commonly outsourced

No CapEx

Performed in-house Simple

Time to

Results1 to 3 DAYS turnaround Rapid – 10 MINUTE test Faster

Cost per Test (U.S.) $150 - $300 (U.S.) $110 - $125Better

Value

Significant

Related

Costs

~ $1,000 to $3,000 pharmacy

costs

~ $2,000 to $6,000

extended length of hospital stay

None for 80%+

of patients

testing negative

Key

Value

Driver

6

Akers’ rapid

diagnostic

tests

transform

traditional

healthcare

testing

Example of Customer Value

Customer Value:

Potential to save a typical U.S. hospital well over $1 Million annually

There are 4 million tests for Heparin-induced thrombocytopenia every year in the U.S. alone using slower, traditional methods

Technology Platform DescriptionProduct

Example

MPC™ - Micro Particle

Catalyzed Biosensor

Permits the rapid determination of

biomarkers in breath condensate

PIFA® - Particle

ImmunoFiltration Assay

Selective filtration of

microparticles in response to

antibody / antigen binding

REA ™ - Rapid Enzymatic

Assay

Detection of blood and urine

metabolites through enzymatic

chemistries in quantitative or

semi-quantitative formats

seraSTAT®Rapid production of Serum from

Whole Blood in minutes through

the use of membrane technology

SMC ™ - Synthetic

Macrocycle Complex

Novel organic macrocyclic

compounds and electronic

readers determine quantitative

levels of therapeutic drugs

Not yet commercialized

minDNAAnalysis of DNA in one minute

using a hand-held readerNot yet commercialized

6 proprietary

technology

platforms

provide the

foundation

for product

development

and external

licensing

7

Overview of Selected Commercialized Products

8

Ma

rke

t

Op

po

rtu

nit

y

4 million HIT tests conducted annually in the U.S. alone – all of which could be

replaced with Akers’ PIFA test

Usa

ge

Results within 10 minutes vs. 24-72 hours for outsourced lab results

Reduces unnecessary costs incurred with standard protocols, saving a typical

U.S. hospital > $1 Million per year

Sta

tus

SellingS

ale

s

Ch

an

ne

ls

To hospitals and clinics via:

• Leading U.S. medical device distributors

• Direct sales force

• Telesales partner

• Internationally via in-country distribution partners

9

The only rapid

test to detect a

potentially fatal

allergy (HIT) to

the blood

thinner Heparin

HIT = Heparin-Induced Thrombocytopenia

42,000

96,000

2013 2014

Growing Device Unit Sales

10

Akers Wellness

LyncTM

New,

personalized

approach to

informing the

current Health

& Wellness of

an individual

Ma

rke

t

Op

po

rtu

nit

y

Antioxidants and weight loss products - multi-billion dollar markets.

Akers Wellness LyncTM provides valuable health information in a consumer-

friendly format

Usa

ge

Akers Wellness LyncTM – app-enabled, multi-device reader, providing easy,

quantified personal health information

METRON® – Breath-based device providing rapid, non-invasive identification of

optimal fat-burning state for weight loss (nutritional ketosis)

VIVO® – Breath-based device providing rapid, non-invasive determination of free

radical levels and the efficacy of antioxidant supplementationS

tatu

s

METRON and VIVO – launched

Akers Wellness LyncTM – available Q2 2015

Sa

les

Ch

an

ne

ls Distribution via Health and Wellness companies

• Multi-level marketing organizations

• Weight loss centers

• Health and fitness clubs

11

Further

products

generating

revenues now

in high margin

markets

Tri-Cholesterol “Check”BreathScan® alcohol

detector

The only combined rapid test for

Total, HDL and LDL cholesterol

The only portable, disposable

alcohol breathalyzer in the US

Overview of Selected Pipeline Products

12

Ma

rke

t

Siz

e

LUNG CANCER: > 1.6 million people worldwide diagnosed annually

ASTHMA: 300 million people worldwide diagnosed; prevalence up to 18%

COPD: 210 million people currently in treatment; up to 1 billion smokers at risk

Usa

ge Single-use, non-invasive device for pulmonary health screenings with the

capacity to dramatically change the speed and cost of diagnosing major

respiratory conditions

Sta

tus

In commercial development

Next

Ste

ps

File 510(k) for FDA clearance. In order of filing: Asthma, COPD, Lung Cancer

Seek distribution as companion diagnostics with prescription medicines; partner

with primary care-based diagnostic sales organizations and distributors that

market to retail health clinics

13

Breath

PulmoHealth

Breath tests for

biomarkers

indicating Lung

Cancer,

Asthma and

COPD

Our rapid tests replace current testing methods

14

Multiple rapid

tests are

being

developed in

large

diagnostic

markets

• Chlamydia test

• Diabetic ketoacidosis breath test

• Asthma breath test

• Lung cancer breath test

• Chronic Obstructive Pulmonary Disease

breath test

• Malaria test

• Dengue Fever test

• Heart attack test

2015 Launch 2016/7 Launch

H1 2015 FY 2014

• Revenues: $1,476,970 $4,427,174

• Gross Profit: $909,603 $3,251,942

• Profit Before Tax: $(3,408,028) $(3,127,167)

• Earnings Per Share: $(0.66) $(0.66) Akers is

growing

revenues

year-on-year

15

FY 2012 FY 2013 FY 2014

$1.5m

$3.6m

$4.4m

As at

Jun 30, 2015 Dec 31, 2014

Cash & Marketable Securities$6,677,360 $9,720,802

Total Assets$13,284,292 $16,650,872

Total Liabilities$1,164,979 $1,843,986

Total Equity $12,119,313 $14,806,886

16

A strong

balance sheet

gives Akers

the resources

to develop

and grow

Raymond F. Akers, Jr. Ph.D. John C. Cheneval

Founder, Executive Chairman of the Board Senior Vice President, Sales and Marketing

30+ years in medical diagnostics; founded Akers in 1989

Invented most of Akers’ products and technologies; holds numerous patents

Ph.D. in Neurochemistry, Northwestern University

25+ years high level industry experience including within Johnson & Johnson, Novartis Molecular Diagnostics and Genoptix Medical Labs

Recognized leader in commercializing diagnostic products in healthcare sector

Responsible for launch and management of several hundred million dollars of diagnostic product sales

Nicolas Daurel Christopher Ellis

Vice President, Sales and Marketing, EMEA Vice President, Global Marketing

20+ years experience in international sales

Held similar positions with Trinity Biotech plc, Diagnositica Stago, SA, Roche Diagnostics

Led provider marketing for Vree Health, LLC, a subsidiary of Merck, one of the largest pharmaceutical companies in the world

12 years in various positions of increasing responsibility within sales and marketing at Merck

17

Experienced,

focused

executive

team

Gary M. Rauch George J. Awad

Vice President, Finance Director, Corporate & Legal Affairs

35+ years in accounting, information systems, and operations consulting

Engagements in healthcare, manufacturing and distribution

Registered patent attorney with 18+ years corporate/IP legal/corporate developmentexperience.

Specialization in developing, driving, and deploying full cycle commercialization/growth plans across various technology industries.

Richard E. McKee Adam C. Sobel M.D.

Vice President, Engineering Director, Medical

40+ years in product design, development and consulting for automated manufacturing equipment in medical diagnostics, pharmaceuticals, food, glass, and automotive

Adjunct Professor of Engineering

MD, Internal Medicine, Jefferson Medical College, Philadelphia, PA

Responsibility for overseeing Akers’ clinical trials

Attending physician at Thomas Jefferson University Hospital, Pennsylvania Hospital, Methodist Hospital, Penn Medicine, Main Line Health System, Nazareth Hospital

Member, American Medical Association, American College of Physicians

18

Experienced,

focused

executive

team

19

Supported by

experienced

non-executive

directors

Thomas J. Knox Robert E. Andrews

Non-Executive Co-Chairman of the Board Non-Executive Director

Expertise in health care and finance

Former CEO of United Healthcare of Pennsylvania; Former Chairman of the Board and Chief Executive Officer of Fidelity Insurance Group, Inc.

Candidate for Mayor of Philadelphia (2007) and candidate for Governor of Pennsylvania (2010)

Member of the U.S. House of Representatives for nearly 24 years (New Jersey's 1st congressional district)

Served on Committees for Armed Services, Budget and Education and Labor (as chairman of the Subcommittee on Health, Employment, Labor, and Pensions)

Retired from the House in 2014 to take position as Of Counsel at Dilworth Paxson LLP where he also chairs Government Affairs Group

Brandon T. Knox

Non-Executive Director

Experience in corporate finance and financial management

Currently wealth advisor at Raymond James

Expand sales organization

Leverage costs savings

message

Expand international

distribution in key markets

Establish U.S. partnerships

to distribute Cholesterol

tests and Akers Wellness

products

Diabetic ketoacidosis breath

test

Chlamydia test

Asthma breath test

Lung cancer breath test

COPD breath test

Heart attack test

Clear path to

grow value

1.

Enhance Sales

and

Distribution

2.

Launch

New Rapid

Tests

3.

Develop

New Rapid

Tests

20

21

Summary Growing

Product Portfolio

Growing

Revenues

Growing

Global Market

Multiple products already

generating sales

Large targeted markets

provide dramatic growth

potential

Strong new product pipeline,

with patented technologies

Sales growing year-on-year

Clear path for continued

growth

Underpinned by strong cash

position

Positioned to capitalize on

growth of point-of-care

medical device market

Healthcare cost pressures

favor the value propositions

of Akers’ tests

CONTACT

a: 201 Grove Road, Thorofare, N.J. 08086, USA

t: +1 (856) 848 8698 e: info@akersbio.com tw: @AkersBio

www.akersbio.com